Advisory Research’s Novartis NVS Stock Holding History

Advisory Research’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-310,305	Closed	-$22.5M	–	385
2018 Q1	$22.5M	Buy	310,305 +13,904	+5%	+$1.06M	0.4%	76
2017 Q4	$22.3M	Sell	296,401 -2,423	-0.8%	-$183K	0.37%	78
2017 Q3	$23M	Buy	298,824 +33,214	+13%	+$2.51M	0.37%	76
2017 Q2	$19.9M	Buy	265,610 +178,657	+205%	+$12.7M	0.31%	85
2017 Q1	$5.79M	Buy	+86,953	New	+$5.79M	0.09%	150

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Advisory Research's NVS Position: Q2 2018 in Review

Advisory Research sold out of Novartis (NVS) in Q2 2018, closing a stake of 310,305 shares — an estimated $22.5M sold.

Advisory Research first reported a position in NVS in Q1 2017 and held it in 5 quarters. The position peaked at $23M in Q3 2017. 987 funds tracked by Wall St. Rank hold NVS as of Q2 2018.

Advisory Research reported no remaining Novartis position as of Q2 2018 after selling out during the quarter.
Advisory Research sold 310,305 Novartis shares in Q2 2018, an estimated $22.5M.
Advisory Research first reported a position in Novartis in Q1 2017 and held it in 5 quarters.
Advisory Research's Novartis position peaked at $23M in Q3 2017.
987 funds tracked by Wall St. Rank held Novartis as of Q2 2018.

Based on Advisory Research's 13F filing for Q2 2018, filed 14 Aug 2018.